Intelligence Feed event · Macro · 2026-10-04

    Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial

    Question

    Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial

    Direct answer

    Genmab released clinical data from its Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The therapy achieved a 45.9% objective response rate, an efficacy threshold of interest in an area with limited historical treatment responses. Durability metrics demonstrated a median duration of response of 12.1 months and median progression-free survival of 9.5 months, supporting continued clinical pipeline development and regulatory engagement.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-04
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/market-events/2026-10-04/genmab-reports-45-9-orr-in-phase-2-rainfol-01-ovarian-cancer-trial-053697

    MACRO
    Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial
    Genmab released clinical data from its Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The therapy achieved a 45.9% objective response rate, an efficacy threshold of interest in an area with limited historical treatment responses. Durability metrics demonstrated a median duration of response of 12.1 months and median progression-free survival of 9.5 months, supporting continued clinical pipeline development and regulatory engagement.
    GMAB
    Impact
    62
    OCT 4
    SIG
    88%
    GMAB
    Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial
    Genmab released clinical data from its Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The therapy achieved a 45.9% objective response rate, an efficacy threshold of interest in an area with limited historical treatment responses. Durability metrics demonstrated a median duration of response of 12.1 months and median progression-free survival of 9.5 months, supporting continued clinical pipeline development and regulatory engagement.
    → Positive Phase 2 oncology efficacy data expands the addressable revenue potential for Genmab's proprietary ADC pipeline and derisks late-stage regulatory milestones.
    Impact
    Genmab released clinical data from its Phase 2 RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S) in patients with platinum-resistant ovarian cancer. The therapy achieved a 45.9% objective response rate, an efficacy threshold of interest in an area with limited historical treatment responses. Durability metrics demonstrated a median duration of response of 12.1 months and median progression-free survival of 9.5 months, supporting continued clinical pipeline development and regulatory engagement.
    Affected
    GMAB
    Transmission
    Positive Phase 2 oncology efficacy data expands the addressable revenue potential for Genmab's proprietary ADC pipeline and derisks late-stage regulatory milestones.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    GMABclinical pipeline derisking and ADC market opportunityUp1-5dGenmab reported 45.9% ORR and 9.5 months mPFS in Phase 2 RAINFOL-01 trial.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month